Table 2.
Gene set enrichment analysis of T3-regulated genes. The table shows specific pathways and the main processes for which genes participate in each tissue.
| Pathway T3 specific | Main Theme | Cerebellum | Thalamus-p | Liver |
|---|---|---|---|---|
| Lysine metabolism | Amino acid metabolism | |||
| Phenylalanine and Tyrosine metabolism | * | |||
| Ubiquitin-dependent Protein Degradation | * | |||
| Amino sugars synthesis | Carbohydrate metabolism | * | ||
| Galactose metabolism | * | * | ||
| Mannose metabolism | * | |||
| L-sugars oxidation | * | |||
| N-Glycan biosynthesis | * | |||
| Adherens Junction Regulation | Cell community | * | ||
| Gap Junction Regulation | * | * | * | |
| Focal Junction Assembly | * | |||
| Tight Junction Assembly (Occludin) | * | |||
| TLR -> AP-1 signalling | * | |||
| TNFR -> CREB/ELK-SRF signaling | * | |||
| Apoptosis | Cell growth and death | * | ||
| Cleavage of Lamina in Apoptosis | * | |||
| AGER -> CREB/SP1 signalling | Cell signalling | * | ||
| AngiopoietinR -> STAT signalling | * | |||
| CannabinoidR -> AP-1/EGR signaling | * | |||
| CCR1 -> STAT signalling | * | |||
| CCR2/5 -> STAT signalling | * | |||
| CCR5 -> TP53 signalling | * | |||
| CD19 -> AP-1/ELK-SRF signalling | * | |||
| CholinergicRm -> CREB/ELK-SRF signaling | * | |||
| EctodysplasinR -> AP-1 signalling | * | |||
| EctodysplasinR -> LEF1 signalling | * | |||
| EGFR -> CTNND signalling | * | |||
| EGFR/ERBB2 -> CTNNB signalling | * | |||
| EGFR -> SMAD1 signalling | * | |||
| EGFR -> ZNF259 signalling | * | |||
| EphrinR -> actin signalling | * | |||
| ErythropoietinR -> ELK-SRF/FOS signalling | * | |||
| FcIgER -> NFATC1 signalling | * | |||
| FGFR1 -> STAT signalling | * | |||
| Guanylate Cyclase Pathway | * | |||
| IL1R -> STAT3 signalling | * | |||
| IL8R -> CREB/EGR signalling | * | |||
| NeuropeptideYR -> ATF/CREB signalling | * | |||
| NeurotensinR -> ELK-SRF/AP-1/EGR signalling | * | |||
| NTRK -> FOXO/MYCN signalling | * | |||
| OxytocinR -> ELK-SRF/GATA/AP-1 signalling | * | |||
| SerotoninR1 -> FOS signalling | * | |||
| TachykininR -> ELK-SRF signalling | * | |||
| ThromboxaneR -> CREB signalling | * | |||
| TNFRSF1A -> STAT signalling | * | |||
| VasopressinR2 -> MEF/MYOD/NFATC/MYOG signalling | * | |||
| VEGFR -> NFATC signalling | * | |||
| Single-Strand Nucleotide Excision DNA Repair | DNA replication and repair | * | ||
| Pyruvate metabolism | Energy metabolism | * | ||
| Tricarboxylic acid cycle | * | |||
| AGER -> NF-kB signalling | Immune system | * | * | |
| Alternative Complement Pathway | * | |||
| B-cell receptor -> NF-kB signalling | * | |||
| B-cell receptor -> NFATC signalling | * | |||
| CD19 -> NF-kB signalling | * | |||
| Classical Complement Pathway | * | |||
| EctodysplasinR -> NF-kB signalling | * | |||
| FibronectinR -> NF-kB signalling | * | |||
| GHR -> NF-kB signalling | * | * | ||
| IL12R -> NF-kB/NFATC signalling | * | |||
| IL15R -> NF-kB/NFATC signalling | * | * | ||
| IL7R -> FOXO/NF-kB signalling | * | * | ||
| Lectin-induced Complement Pathway | * | |||
| MacrophageR -> CEBPB/NF-kB signalling | * | |||
| Mast Cell Activation | * | |||
| NK Cell Activation | * | |||
| PTAFR -> NF-kB signalling | * | |||
| T Cell Activation | * | |||
| T-cell receptor -> AP-1 signalling | * | |||
| T-cell receptor -> NF-kB signalling | * | * | ||
| T-cell receptor -> NFATC signalling | * | |||
| TLR4/5/7/9 -> NF-kB signalling | * | |||
| Ganglioside-type glycosphingolipid biosynthesis | Lipid metabolism | * | ||
| Globoside-type glycosphingolipid biosynthesis | * | |||
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | * | |||
| Metabolism of triacylglycerols | * | |||
| Omega-6-fatty acid metabolism | * | |||
| Sphingolipid metabolism | * | |||
| Purine metabolism | Nucleotide metabolism | * | ||
| Ascorbate biosyntesis | Other | * | ||
| Extracellular Matrix Turnover | * | |||
| Ethanol metabolism | * | |||
| Gonadotrope Cell Activation | * | |||
| Melanogenesis | * | * | * | |
| Skeletal Myogenesis Control | * | * | ||
| Histone Ubiquitination | Transcription | * | ||
| Lacto- and neolacto-type glycosphingolipid biosynthesis | * | |||
| RNA Gene Silencing | * | |||
| mRNA Degradation | * | |||
| Secretory Pathway: Golgi Transport | * |